Vise Technologies Inc. Takes Position in Kenvue Inc. (NYSE:KVUE)

Vise Technologies Inc. purchased a new position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 11,317 shares of the company's stock, valued at approximately $242,000.

Several other hedge funds have also recently modified their holdings of KVUE. Geneos Wealth Management Inc. acquired a new stake in Kenvue in the fourth quarter valued at about $29,000. SRS Capital Advisors Inc. raised its stake in shares of Kenvue by 67.4% during the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock worth $30,000 after buying an additional 571 shares in the last quarter. Asset Planning Inc acquired a new stake in shares of Kenvue in the 4th quarter valued at approximately $42,000. Clarity Asset Management Inc. purchased a new stake in shares of Kenvue in the fourth quarter valued at approximately $45,000. Finally, SBI Securities Co. Ltd. acquired a new position in Kenvue during the fourth quarter worth $46,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. UBS Group raised their target price on Kenvue from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Friday, May 9th. Evercore ISI initiated coverage on shares of Kenvue in a research note on Monday, March 24th. They issued an "in-line" rating and a $25.00 price objective for the company. Royal Bank of Canada restated a "sector perform" rating and set a $24.00 target price on shares of Kenvue in a research report on Monday, February 3rd. Citigroup boosted their price target on Kenvue from $22.00 to $24.50 and gave the stock a "neutral" rating in a research note on Friday, May 9th. Finally, Barclays raised their price target on Kenvue from $22.00 to $23.00 and gave the company an "equal weight" rating in a research report on Monday, May 12th. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $25.33.

Kenvue Trading Down 0.9%

Kenvue stock traded down $0.21 during midday trading on Monday, reaching $23.67. The stock had a trading volume of 9,774,685 shares, compared to its average volume of 16,319,737. The stock's 50-day simple moving average is $23.28 and its 200 day simple moving average is $22.63. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $25.17. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The stock has a market capitalization of $45.41 billion, a PE ratio of 44.65, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.24 EPS for the quarter, topping analysts' consensus estimates of $0.23 by $0.01. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. The company had revenue of $3.74 billion for the quarter, compared to the consensus estimate of $3.69 billion. During the same period last year, the business posted $0.28 EPS. The company's quarterly revenue was down 3.9% compared to the same quarter last year. Analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th were given a dividend of $0.205 per share. The ex-dividend date was Wednesday, May 14th. This represents a $0.82 dividend on an annualized basis and a yield of 3.47%. Kenvue's dividend payout ratio (DPR) is 149.09%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.